Teraoka, Yuji <br/><br/>
Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.  [electronic resource] 

 -  The Journal of general virology  08 2018 
 - 1058-1065 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1465-2099 
<br/><br/><label>Standard No.: </label>10.1099/jgv.0.001091  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antiviral Agents--administration & dosage<br/>Benzazepines--administration & dosage<br/>Biomarkers<br/>Carbamates<br/>Drug Combinations<br/>Drug Resistance, Viral<br/>Drug Therapy, Combination<br/>Genotype<br/>Hepacivirus--drug effects<br/>Hepatitis C--drug therapy<br/>Humans<br/>Imidazoles--administration & dosage<br/>Indoles--administration & dosage<br/>Isoquinolines--administration & dosage<br/>Mice<br/>Protease Inhibitors--administration & dosage<br/>Pyrrolidines<br/>Sulfonamides--administration & dosage<br/>Treatment Failure<br/>Valine--analogs & derivatives<br/>Viral Nonstructural Proteins--antagonists & inhibitors<br/>Viremia